Amikacin is removed in a negligible amount through milk. The limited pharmacokinetic data indicate that the concentration in human milk may be very low, from trace to 1.5 mg / L, so it is unlikely to pass the infant in an amount large enough to affect him. However, there are no observations published in the literature about the influence on the baby, although it is estimated that the potential effects would be limited to infant gut, with occurrence of diarrhea or signs of oral-genital candidiasis.
Warning of the manufacturer:
There are no data on excretion in breast milk. As a general rule it is recommended that women treated with amikacin suspend breastfeeding due to potential adverse effects on the infant.